ReviewBioImpacts : BI2026
Efficacy of nutraceuticals as adjunctive therapies in autoimmune diseases: A systematic review of clinical trials.
Review in BioImpacts : BI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Autoimmune diseases are characterized by a dysregulation of the immune system, resulting in chronic inflammation and tissue damage. Although immunosuppressive therapies have advanced, their limited efficacy and the adverse effects associated with long-term use restrict their clinical utility, highlighting the need for alternative treatments. This study aimed to synthesize current evidence on the efficacy of nutraceutical interventions for these disorders. Methods: A comprehensive search was conducted on PubMed, Embase, and ClinicalTrials.gov to identify studies published between 2010 and 2025 evaluating nutraceutical supplementation in patients with autoimmune diseases. Study selection and data extraction were performed according to predefined inclusion criteria. Results: Thirty clinical trials involved 2,107 participants with rheumatoid arthritis, psoriasis, multiple sclerosis, systemic lupus erythematosus, or Hashimoto's thyroiditis. Interventions included polyphenols, vitamins, minerals, omega-3 fatty acids, and probiotics, administered over 4 to 48 weeks, with sample sizes ranging from 24 to 351 participants. The studies demonstrated anti-inflammatory and immunoregulatory effects, as well as improvements in disease activity and clinical symptoms following supplementation with curcumin, probiotics, vitamin D, omega-3 fatty acids, baicalin, resveratrol, and quercetin. Additionally, reductions in autoantibody levels were observed after supplementation with curcumin, selenium, and genistein. Conclusion: The available evidence suggests that these nutraceuticals are emerging as candidates with therapeutic potential for integration as adjunctive therapies in the management of autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.